© Copyright 2013-2016 Fagron. Todos os direitos reservados.

Sobre a Fagron
E-News
Contatos

A Fagron é uma multinacional holandesa, presente em mais de 30 países e com produtos comercializados em mais de 60. Fundamentada em pesquisa e desenvolvimento científico magistral, a Fagron é líder mundial em medicamentos farmacêuticos customizados para hospitais, farmácias, médicos e pacientes.

Assine para receber nossa Newsletter.

Área exclusiva para profissionais da saúde.*

 

“A fase neógena e uma nova era para o tratamento de alopecia.”

Protocolos de Tratamento

Tabela de compatibilidade

 Tabela com principais API’s e DCI’s utilizados na dermatologia para os tratamentos das alopecias e outras condições afetando os cabelos e o couro cabeludo como caspa e dermatite seborreica, além de DCI’s utilizados na tricologia. 

Bansal M, Manchanda K, Pandey SS. Role of caffeine in the management of androgenetic alopecia. Int J Trichology. 2012 Jul;4(3):185-6. doi: 10.4103/0974-7753.100096.

Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM, Lammers KM. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003 Aug;149(2):354-62.

Borda LJ, Wikramanayake TC. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J Clin Investig Dermatol. 2015 Dec;3(2). doi: 10.13188/2373-1044.1000019. Epub 2015 Dec 15.

Buechner S. Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2 % ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 2014 Jun;25(3):226-31. doi: 10.3109/09546634.2013.782092. Epub 2013 May 21.

Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016 Jan;54(1):19-27. doi: 10.5414/CP202467.

Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2α analogs: beyond the eyelashes. J Am Acad Dermatol. 2015 Apr;72(4):712-6. doi: 10.1016/j.jaad.2014.10.012. Epub 2015 Jan 16.

Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 2010 Apr;24(4):481-5. doi: 10.1111/j.1468-3083.2009.03543.x. Epub 2009 Dec 17.

Fertig R, Tosti A. Frontal fibrosing alopecia treatment options. Intractable Rare Dis Res. 2016 Nov;5(4):314-315.

Hasanzadeh H, Nasrollahi SA, Halavati N, Saberi M, Firooz A. Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction. Acta Dermatovenerol Alp Pannonica Adriat. 2016 Sep;25(3):41-44.

Ingprasert S, Tanglertsampan C, Tangphianphan N, Reanmanee C. Efficacy and safety of minoxidil 3% lotion for beard enhancement: A randomized, double-masked, placebo-controlled study. J Dermatol. 2016 Feb 19. doi: 10.1111/1346-8138.13312.

Inui S, Itami S. Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity. J Dermatol Sci. 2007 Jan;45(1):66-8. Epub 2006 Sep 25.

Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. J EurAcadDermatolVenereol. 2015 Sep 21. doi: 10.1111/jdv.13324.

Kelly Y, Blanco A, Tosti A. Androgenetic Alopecia: An Update of Treatment Options. Drugs. 2016 Sep;76(14):1349-64. doi: 10.1007/s40265-016-0629-5.

Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A. Randomized Comparison of Topical Betamethasone Valerate Foam, Intralesional Triamcinolone Acetonide and Tacrolimus Ointment in Management of Localized Alopecia Areata. International Journal of Trichology. 2011;3(1):20-24. doi:10.4103/0974-7753.82123.

Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol. 2014 Feb;41(2):149-52. doi: 10.1111/1346-8138.12275. Epub 2013 Nov 8.

Mancuso G, Balducci A, Casadio C, Farina P, Staffa M, Valenti L, Milani M. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol. 2003 Jul;42(7):572-5.

Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-7.

Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Int J Cosmet Sci. 2002 Oct;24(5):249-56. doi: 10.1046/j.1467-2494.2002.00145.x.

Rossi A, Anzalone A, Fortuna MC, Caro G, Garelli V, Pranteda G, Carlesimo M. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther. 2016 Nov;29(6):424-432. doi: 10.1111/dth.12390. Epub 2016 Jul 18.

Sampaio AL, Mameri AC, Vargas TJ, Ramos-e-Silva M, Nunes AP, Carneiro SC. Seborrheic dermatitis. An Bras Dermatol. An Bras Dermatol. 2011 Nov-Dec;86(6):1061-71; quiz 1072-4.

Sheikh S, Ahmad A, Ali SM, Ahmad MU, Paithankar M, et al. A New Topical Formulation of Minoxidil and Finasteride Improves Hair Growth in Men with Androgenetic Alopecia. J Clin Exp Dermatol Res 6:253. doi:10.4172/2155-9554.1000253. J Clin Exp Dermatol Res 2015, 6:1.

Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol. 2007;8(5):285-90.

Spano F, Donovan JC. Alopecia areata: Part 2: treatment. Canadian Family Physician. 2015;61(9):757-761.

Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012 Oct;95(10):1312-6.

Tosti A, Piraccini BM, Iorizzo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol. 2005 Jan;52(1):55-60.

Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003 Jul;49(1):96-8.

van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016 May 26;(5):CD007628. doi: 10.1002/14651858.CD007628.pub4.

 As declarações de compatibilidade nesta tabela se aplicam aos intervalos de dosagens tópicas geralmente prescrito para API’s e DCI’s. 

Salvo disposição em contrário, as informações referem-se a preparações com prazo de uso de até 90 dias.

Consulte o seu médico especialista e saiba mais sobre a linha TrichoConcept™.

*A Fagron é fundamentada em pesquisa e desenvolvimento científico magistral em que são consideradas as características exclusivas de cada paciente. Todas as decisões relacionadas aos tratamentos de pacientes devem ser tomadas por profissionais autorizados. Nunca utilize medicamentos por conta própria.